Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a “springboard year,” driven in part by what he described as a significant amount of ...
Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.
Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...
From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of ...
Repatha, first approved in 2015, has been used by more than 6.7 million patients globally. Earlier this year, the FDA broadened its approved use to include adults at increased risk for major adverse ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Amgen Inc. is conducting ...
Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...
Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...
Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback